Research Article, Int J Cardiovasc Res Vol: 2 Issue: 2
The Novel Development of an Experimental Model of Dihydropyridine Calcium Channel Blocker Poisoning using Intravenous Amlodipine
| David Jang1*, Sean Donovan2, Theodore Bania2, Lewis Nelson3, Robert Hoffman3 and Jason Chu4 | |
| 1New York University School of Medicine, USA | |
| 2Department of Emergency Medicine St. Luke’s-Roosevelt Hospital Center, USA | |
| 3Department of Emergency Medicine New York University School of Medicine Bellevue Hospital Center New York, New York, USA | |
| Corresponding author : David Jang Assistant Professor, New York University School of Medicine, USA E-mail: Jangd01@nyumc.org |
|
| Received: February 28, 2013 Accepted: March 04, 2013 Published: March 29, 2013 | |
| Citation: Jang D, Donovan S, Bania T, Nelson L, Hoffman R, et al. (2013) The Novel Development of an Experimental Model of Dihydropyridine Calcium Channel Blocker Poisoning using Intravenous Amlodipine. Int J Cardiovasc Res 2:2. doi:10.4172/2324-8602.1000121 |
Abstract
The Novel Development of an Experimental Model of Dihydropyridine Calcium Channel Blocker Poisoning using Intravenous Amlodipine
Cardiovascular drug poisoning remains a leading cause of fatality. Within this class, calcium channel blockers(CCBs) account for the majority of deaths. CCBs are typically categorized as dihydropyridines (i.e. amlodipine or nifedipine) versus the non-dihydropyridine (i.e. verapamil and diltiazem) which are the most potent and once considered the CCB type responsible for all CCB-related deaths. Most recently, dihydropyridine deaths have increased. While there are established models of nondihydropyridine poisoning there currently are no established experimental models of dihydropyridine poisoning.
